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matrix metalloproteinases play a significant role in cartilage de- 
struction. 
Objective: To determine if RAR-alpha is expressed in the syn- 
ovial membrane (SM) of patients with OA. 
Methods: SM specimens from 17 patients with OA and 14 pa- 
tients with rheumatoid arthritis (RA), obtained during joint re- 
placement, were used in this study. SM cryostat sections were 
stained for RAR-alpha using the ABC indirect immunoperoxi- 
dase method with anti-RAR-alpha rabbit polyclonal antibody (c- 
20; Santa Cruz). The specificity of anti-RAR-alpha polyclonal an- 
tibody was tested with western blotting. 
Results: Immunoreactivity for RAR-alpha was detected in SM 
biopses from all patients with OA and RA. It was present in 
around 30% of mononuclear cells in nodular infiltrates, as well as 
in endothelial cells, synovial lining cells, and fibroblast-like cells. 
Conclusion: The presence of RAR-alpha in SM of patients with 
OA suggests that RAR-alpha may play a role in cartilage destruc- 
tion in OA. 
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Purpose: Transfersome ® carriers are ultradeformable vesicles 
designed to deliver drugs non-invasively through the skin barrier 
to target muscles and joints without being cleared by the cuta- 
neous microcirculation. Ketoprofen is an NSAID analgesic with 
potent additional ocal anti-inflammatory properties. This study 
compared the safety and efficacy of 110 mg of ketoprofen in 
Transfersome ® Gel (IDEA-033) applied dermally twice daily (bid) 
with that of celecoxib (100 mg orally bid) and placebo in treating 
the signs and symptoms of OA of the knee. 
Methods: This 6-week, multicenter, randomized, double-blind, 
double-dummy, parallel-group study was conducted in 397 sub- 
jects with knee OA who were experiencing at least moderate pain 
when not taking analgesic medication. To qualify for the study, 
subjects met the following flare criteria for the index knee at the 
baseline visit: pain with walking of at least 40 mm on the WOMAC 
visual analogue scale (VAS), an increase in pain with walking of 
at least 15 mm on the WOMAC VAS at baseline compared to 
screening, and a physician's global assessment of OA of grade 3 
to 5 and at least a 1 -grade increase from screening. 
Results: 3 co-primary endpoints were defined a priori. In the 
intent-to-treat (ITT) analysis, for the WOMAC pain subscale, 
both IDEA-033 (p= 0.0041) and celecoxib (p= 0.0004) showed 
a statistically significant improvement in the least squares (LS) 
mean change from baseline at Week 6 vs. placebo. For the 
WOMAC physical function subscale, celecoxib showed a signifi- 
cant (p= 0.0100) improvement in the LS mean change from base- 
line at Week 6 vs. placebo; the improvement for IDEA-033 vs. 
placebo approached statistical significance (p=0.077). For Patient 
Global Assessment, both IDEA-033 (p= 0.0015) and celecoxib 
(p= 0.0145) showed a statistically significantly higher response 
to therapy at Week 6 for the LS mean values vs. placebo. Anal- 
ysis of the primary efficacy endpoints by study week proved that 
both IDEA-033 and celecoxib were associated with progressive 
improvement over the six-week study period. The results of the 
per-protocol analysis were generally consistent with the ITT anal- 
ysis; however, for the WOMAC physical function subscale, the 
improvement after 6 weeks with IDEA-033 was significantly (p= 
0.0118) greater than with placebo. IDEA-033 was well tolerated. 
Overall, 53.6% of subjects treated with IDEA-033, 50.0% of sub- 
jects treated with celecoxib, and 48.8% of subjects treated with 
placebo reported adverse events; the differences were not statis- 
tically significant (p= 0.7116). 
Conclusions: IDEA-033 was superior to placebo for 2 of the 3 
primary efficacy measures in the ITT population and for all 3 pri- 
mary efficacy measures in the per-protocol population. The study 
medications were generally well tolerated. The severity and na- 
ture of adverse events were generally similar among groups. 
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Aim: Cathepsin K is expressed in articular cartilage and synovial 
fibroblasts and has the capacity to degrade several bone and car- 
tilage matrix components including collagen types 1,2 and aggre- 
can indicating a potential role of cathepsin K in OA pathology. We 
have identified SB-553484 as an orally available potent inhibitor 
of dog cathepsin K (Ki = 200 pM) that exhibits 4-80 fold selectivity 
over other cathepsins uch as L, S and B. This study investigated 
the effects of SB-553484 on chondroprotection i  the dog menis- 
cectomy model of OA. 
Methods: Female beagle dogs had unilateral partial medial 
meniscectomy on the left knee and were treated with vehicle 
(n=20) or SB-553484, po, bid, at 50 mg/kg (n=20) beginning 1 
day before and continuing for 4 weeks post surgery. Left knees 
were evaluated 4 weeks post surgery for effects of treatment on 
gross and microscopic histological changes. Parameters for the 
groups were com pared using the Student's t-test with significance 
set at p_< 0.05. 
Results: All dogs tolerated the treatment and exhibited normal 
activity and appetite. Typical degenerative changes characterized 
by the presence of focal, well circumscribed lesions of cartilage 
degeneration were present on the medial tibias and to lesser 
extent on femoral condyles of all dogs in the vehicle control 
group. Subjective gross cartilage degeneration scores were de- 
creased significantly by 29% in SB-553484 treated dogs. Calcu- 
lated (length X width X depth) gross tibial scores were decreased 
significantly by 46% in SB-553484 treated dogs. Combined sub- 
jective tibial and femoral cartilage degeneration scores were de- 
creased significantly by 28% in SB-553484 treated dogs whereas 
calculated summed scores were decreased non-significantly by 
39%. Histopathological evaluation of the vehicle-treated ogs re- 
vealed typical degenerative changes with the most severe tibial 
lesions in the mid-tibia. Summed tibial cartilage degeneration de- 
creased significantly by 21% in the SB-553484 group. Inhibition 
of cartilage degeneration in 4 zones from outside (1) to far in- 
side (4) was significant for zone 1 (32%) and 16-22% for all other 
zones. Significant tibial cartilage degeneration width was non- 
significantly decreased by 21%. Overall depth ratio of any tibial 
matrix change was decreased significantly by 28% and the range 
of decrease across the 4 zones was 17-53%. 
Conclusion: In summary, this study demonstrated mild to mod- 
erate beneficial effects of oral treatment with SB-553484 on gross 
and histopathological parameters measured in meniscectomy in- 
duced cartilage degeneration in beagle dogs. The data suggest 
that targeting cathepsin K may represent a valid strategy for phar- 
maceutical intervention in osteoarthritis. 
